
Volastra highlights AACR 2026 data on an Rb pathway-driven strategy for KIF18A inhibitors
Volastra Therapeutics Announces Biomarker and Combination Data around AACR 2026 Defining an Rb Pathway-Driven Pan-Cancer Development Strategy for KIF18A Inhibitors Volastra Therapeutics, a clinical-stage oncology company pioneering therapies targeting chromosomal instability (CIN), announced multiple scientific disclosures coinciding with the American…











